First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

BACKGROUND: ACAM2000, a thymidine kinase (TK)-positive strain of vaccinia virus, is the current smallpox vaccine in the US. Preclinical testing demonstrated potent oncolytic activity of ACAM2000 against several tumor types. This Phase I clinical trial of ACAM2000 delivered by autologous adipose stro...

Descripción completa

Detalles Bibliográficos
Autores principales: Minev, Boris R., Lander, Elliot, Feller, John F., Berman, Mark, Greenwood, Bernadette M., Minev, Ivelina, Santidrian, Antonio F., Nguyen, Duong, Draganov, Dobrin, Killinc, Mehmet O., Vyalkova, Anna, Kesari, Santosh, McClay, Edward, Carabulea, Gabriel, Marincola, Francesco M., Butterfield, Lisa H., Szalay, Aladar A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699108/
https://www.ncbi.nlm.nih.gov/pubmed/31426803
http://dx.doi.org/10.1186/s12967-019-2011-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699108/
https://www.ncbi.nlm.nih.gov/pubmed/31426803
http://dx.doi.org/10.1186/s12967-019-2011-3

Ejemplares similares